May 19, 2017 07:42 AM EDTUpdated May 19, 08:49 PM
Pharma

Mer­ck’s check­point star Keytru­da grabs an­oth­er FDA OK, steer­ing past wreck­age of a Roche dis­as­ter

John Carroll

Editor & Founder

Mer­ck’s Keytru­da con­tin­ues to make a rapid ad­vance to new ap­provals for ex­pand­ed use. This time the FDA is ap­prov­ing their PD-1 drug for sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times